

Steve Sisolak
Governor

Richard Whitley, MS
Director



DEPARTMENT OF HEALTH AND HUMAN SERVICES

DIVISION OF HEALTH CARE FINANCING AND POLICY

Helping people. It's who we are and what we do.



Suzanne Bierman,
JD MPH
Administrator

REVISED NOTICE OF PUBLIC MEETING – SILVER STATE SCRIPTS BOARD

Date of Posting: ~~August 18, 2021~~
August 31, 2021

Date of Meeting: Thursday, September 23, 2021, at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Silver State Script Board.

Place of Meeting: [Microsoft Teams](#)

OR

<https://tinyurl.com/SSSB092321>

The physical location for this meeting which is open to the public is at:

Springs Preserve
333 South Valley View Blvd
Las Vegas, NV 89107
(702) 822-7700

Please check with staff to verify room location.

Space is limited at the physical location and subject to any applicable social distancing or mask wearing requirements as may be in effect at the time of the meeting for the county in which the physical meeting is held.

Note: *If at any time during the meeting an individual who has been named on the agenda or has an item specifically regarding them included on the agenda is unable to participate because of technical or other difficulties, please email rxinfo@dhcfp.nv.gov and note at what time the difficulty started so that matters pertaining specifically to their participation may be continued to a future agenda if needed or otherwise addressed.*

Meeting Audio Information: Phone: (952) 222-7450
Event: 999 587 133#

PLEASE DO NOT PUT THIS NUMBER ON HOLD (hang up and rejoin if you must take another call)

YOU MAY BE UNMUTED BY THE HOST WHEN SEEKING PUBLIC COMMENT, PLEASE HANG UP AND REJOIN IF YOU ARE HAVING SIDE CONVERSATIONS DURING THE MEETING

This meeting will be recorded to facilitate note-taking or other uses. By participating you consent to recording of your participation in this meeting.

Closed Executive Session – 1:00 PM

Open Session/Public Meeting – will begin upon completion of the Closed Executive Session

AGENDA

1. Call to Order and Roll Call

2. General Public Comment

*Public comment is encouraged to be submitted in advance so that it may be included in meeting materials and given attention. No action may be taken upon a matter raised through public comment unless the matter itself has been specifically included on an agenda as an action item. Please provide your name in any comment for record keeping purposes. You may submit comments in writing via e-mail to (rxinfo@dncfp.nv.gov). There may be opportunity to take public comment via telephone or the meeting's virtual platform as well as in person opportunities, but phone participants should disconnect their call and re-join if they must take another call. Do not place your phone on hold or you may disrupt the meeting for other participants. Public comment may be limited to three minutes per person. **Note: this guidance applies for all periods of public comment referenced further in the agenda, such as those related to clinical presentations.***

Public comments may be related to topics on the agenda or matters related to other topics per NRS 241.020(3)(3)(II).

3. Administrative

- a. **For Possible Action:** Review and Approve Meeting Minutes from July 29, 2021.
- b. Status Update by DHCFF.

4. Annual Review – Established Drug Classes Being Reviewed Due to the Release of New Drugs

- a. **For Possible Action:** Discussion and possible adoption of Biologic Response Modifiers - Multiple Sclerosis Agents, Oral.
 - i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- b. **For Possible Action:** Discussion and possible adoption of Cardiovascular Agents – Antilipemics - HMG-CoA Reductase Inhibitors (Statins).
 - i. Public comment.
 - ii. Drug class review presentation by OptumRx.

- iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- c. **For Possible Action:** Discussion and possible adoption of Dermatological Agents - Topical Antineoplastics -Topical Retinoids.
- i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- d. **For Possible Action:** Discussion and possible adoption of Psychotropic Agents - ADHD Agents and Psychostimulants Narcolepsy Agents.
- i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- e. **For Possible Action:** Discussion and possible adoption of Respiratory Agents - Short-Acting/Rescue Therapy.
- i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

5. Annual Review - Established Drug Classes Being Reviewed Due to the Release of New Generics

- a. **For Possible Action:** Discussion and possible adoption of Cardiovascular Agents – Antilipemics - Bile Acid Sequestrants
- i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

6. Annual review - Established Drug Classes

- a. **For Possible Action:** Discussion and possible adoption of Anti-infective Agents – Aminoglycosides - Inhaled Aminoglycosides.
- i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- b. **For Possible Action:** Discussion and possible adoption of Biologic Response Modifiers – Targeted Immunomodulators and Multiple Sclerosis Agents, Injectable.
- i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- ~~b-c.~~ **For Possible Action:** Discussion and possible action of Dermatological Agents – Topical Analgesics.
- i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- ~~e-d.~~ **For Possible Action:** Discussion and possible adoption of Gastrointestinal Agents – Gastrointestinal Enzymes.
- i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- ~~e-e.~~ **For Possible Action:** Discussion and possible adoption of Hormones and Hormone Modifiers - Antidiabetic Agents - Incretin Mimetics and Insulins (Vials, Pens and Inhaled).
- i. Public comment.
 - ii. Drug class review presentation by OptumRx.
 - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
 - iv. Presentation of recommendations for PDL inclusion by OptumRx.
 - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- ~~e-f.~~ **For Possible Action:** Discussion and possible adoption of Musculoskeletal Agents - Anticongestants Agents.

- i. Public comment.
- ii. Drug class review presentation by OptumRx.
- iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
- iv. Presentation of recommendations for PDL inclusion by OptumRx.
- v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

f.g. **For Possible Action:** Discussion and possible adoption of Neurological Agents - Antiparkinsonian Agents - Dopamine Precursors; Neurological Agents - Anti-Migraine Agents - Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists and Serotonin-Receptor Agonists.

- i. Public comment.
- ii. Drug class review presentation by OptumRx.
- iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
- iv. Presentation of recommendations for PDL inclusion by OptumRx.
- v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

g.h. **For Possible Action:** Discussion and possible adoption of Ophthalmic Agents - Ophthalmic Antihistamines.

- i. Public comment.
- ii. Drug class review presentation by OptumRx.
- iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
- iv. Presentation of recommendations for PDL inclusion by OptumRx.
- v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

h.i. **For Possible Action:** Discussion and possible adoption of Respiratory Agents - Long-acting/Maintenance Therapy.

- i. Public comment.
- ii. Drug class review presentation by OptumRx.
- iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
- iv. Presentation of recommendations for PDL inclusion by OptumRx.
- v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

7. Annual Review - Drug Classes Without Proposed Changes

- a. Public Comment
- b. **For Possible Action:** Discussion and possible adoption of the Preferred Drug List (PDL) as presented by OptumRx and the Division of Health Care Financing and Policy without changes.
 - i. Analgesics, Analgesic/Miscellaneous, Neuropathic Pain/Fibromyalgia Agents; Tramadol and Related Drugs; Opiate Agonists; Opiate Agonists - Abuse Deterrent; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) – Oral.
 - ii. Antihistamines, Antihistamines, H1 blockers, Non-Sedating H1 Blockers.
 - iii. Anti-infective Agents, Antivirals, Alpha Interferons; Antivirals, Anti-hepatitis Agents, Polymerase Inhibitors/Combination Products; Ribavirins; Anti-Herpetic Agents; Influenza

- Agents; Cephalosporins, Second-Generation Cephalosporins; Macrolides; Quinolones, Quinolones - 2nd Generation; Quinolones - 3rd Generation.
- iv. Autonomic Agents, Sympathomimetics, Self-Injectable Epinephrine.
 - v. Biologic Response Modifiers, Specific Symptomatic Treatment.
 - vi. Cardiovascular Agents, Antihypertensive Agents, Angiotensin II Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors); Beta-Blockers; Calcium-Channel Blockers; Vasodilators, Inhaled; Vasodilators, Oral; Antilipemics, Cholesterol Absorption Inhibitors; Fibrin Acid Derivatives; Niacin Agents; Omega-3 Fatty Acid.
 - vii. Dermatological Agents, Antipsoriatic Agents; ~~Topical Analgesics~~; Topical Anti-infectives, Topical Impetigo Agents; Topical Antivirals, Topical Scabicides; Topical Anti-inflammatory Agents, Immunomodulators: Topical; Topical Anti-infectives, Acne Agents: Topical, Benzoyl Peroxide, Antibiotics and Combination Products.
 - viii. Electrolytic and Renal Agents, Phosphate Binding Agents.
 - ix. Gastrointestinal Agents, Antiemetics, Antiemetics, Pregnancy-induced Nausea and Vomiting Treatment; Serotonin-receptor antagonists/Combo; Antiulcer Agents, H₂ blockers; Proton Pump Inhibitors (PPIs); Functional Gastrointestinal Disorder Drugs; Gastrointestinal Anti-inflammatory Agents.
 - x. Genitourinary Agents, Benign Prostatic Hyperplasia (BPH) Agents, 5-Alpha Reductase Inhibitors; Benign Prostatic Hyperplasia (BPH) Agents Alpha-Blockers; Bladder Antispasmodics.
 - xi. Hematological Agents, Anticoagulants, Oral; Injectable; Erythropoiesis-Stimulating Agents; Platelet Inhibitors.
 - xii. Hormones and Hormone Modifiers, Androgens; Antidiabetic Agents, Alpha-Glucosidase Inhibitors/Amylin analogs/Misc.; Biguanides; Dipeptidyl Peptidase-4 Inhibitors; Meglitinides; Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors; Sulfonylureas; Thiazolidinediones; Anti-hypoglycemic Agents; Pituitary Hormones, Growth hormone modifiers; Progestins for Cachexia.
 - xiii. Monoclonal Antibodies for the treatment of Respiratory Conditions.
 - xiv. Musculoskeletal Agents, Bone Resorption Inhibitors, Bisphosphonates; Nasal Calcitonins; Restless Leg Syndrome Agents; Skeletal Muscle Relaxants.
 - xv. Neurological Agents, Neurological Agents, Alzheimers Agents; Anticonvulsants, Anticonvulsants; Barbiturates; Benzodiazepines; Hydantoins; Antiparkinsonian Agents, Non-ergot Dopamine Agonists.
 - xvi. Ophthalmic Agents, Antiglaucoma Agents; Ophthalmic Antihistamines; Ophthalmic Anti-infectives, Ophthalmic Anti-inflammatory Agents, Ophthalmic Corticosteroids; Antiglaucoma Agents; Ophthalmic Anti-infectives, Ophthalmic Macrolides; Ophthalmic Anti-infectives, Ophthalmic Quinolones; Ophthalmic Anti-infective/Anti-inflammatory Combinations; Ophthalmic Anti-inflammatory Agents, Ophthalmic Nonsteroidal Anti-inflammatory Drugs (NSAIDs); Ophthalmics for Dry Eye Disease.
 - xvii. Otic Agents, Otic Anti-infectives, Otic Quinolones.
 - xviii. Psychotropic Agents, Antidepressants, Other; Selective Serotonin Reuptake Inhibitors (SSRIs); Antipsychotics, Atypical Antipsychotics – Oral and Topical; Long-acting Injectable; Anxiolytics, Sedatives, and Hypnotics; Psychostimulants, Narcolepsy Agents.
 - xix. Respiratory Agents, Nasal Antihistamines; Respiratory Anti-inflammatory Agents, Leukotriene Receptor Antagonists; Nasal Corticosteroids; Phosphodiesterase Type 4 Inhibitors.
 - xx. Toxicology Agents, Antidotes, Opiate Antagonists; Substance Abuse Agents.

8. OptumRx Reports: New Drugs to Market and New Line Extensions

9. Closing Discussion

- a. Public comments on any subject.
(No action may be taken upon a matter raised under public comment period unless the matter itself has been specifically included on an agenda as an action item. Comments will be limited to three minutes per person. Persons making comment will be asked to begin by stating their name for the record and to spell their last name and provide the secretary with written comments.)
- b. **For Possible Action:** Date and location of the next meeting.
- c. Adjournment.

PLEASE NOTE: Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to three minutes.

This notice and agenda have been posted online at <http://dhcfp.nv.gov> and <http://notice.nv.gov> as well as Carson City, Las Vegas, and Reno central offices for the Division of Health Care Financing and Policy. Email notice has been made to such individuals as have requested notice of meetings (to request notifications please contact rxinfo@dhcfp.nv.gov, or at 1100 East William Street, Suite 101, Carson City, Nevada 89701).

If you require a physical copy of supporting material for the public meeting, please contact rxinfo@dhcfp.nv.gov, or at 1100 East William Street, Suite 101, Carson City, Nevada 89701). Limited copies of materials will also be available on site at the meeting's physical location. Supporting material will also be posted online at <http://dhcfp.nv.gov/> and <https://www.medicaid.nv.gov/providers/rx/sssb/SilverStateScriptsBoard.aspx>.

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.

Note: We are pleased to make reasonable accommodations for members of the public with a disability and wish to participate. If accommodated arrangements are necessary, notify the Division of Health Care Financing and Policy as soon as possible and at least ten days in advance of the meeting, by e-mail at rxinfo@dhcfp.nv.gov in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701.